文献速递浆细胞疾病

达雷妥尤单抗治疗多发性骨髓瘤的结局:加拿大骨髓瘤研究组数据库的回顾性队列研究

Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database.
PubMed 文献 · Br J Haematol · 2022-04-05

该回顾性队列研究基于加拿大骨髓瘤研究组数据库(CMRG-DB),纳入583例接受达雷妥尤单抗(dara)为基础方案二线及以上治疗的多发性骨髓瘤(MM)患者。中位随访17.5个月,全队列中位无进展生存期(PFS)和总生存期(OS)分别为13.1和32.9个月;二线治疗的中位PFS和OS分别为23.5和49.1个月,三线降至12.8和43.0个月,四线降至7.0和20.5个月。达雷妥尤单抗单药(联合或不联合糖皮质激素)的中位PFS为3.9个月、OS为17.1个月;联合硼替佐米、来那度胺或泊马度胺的中位PFS和OS分别为8.3和26.2个月、26.8和43.0个月、9.7和31.4个月。这些回顾性数据提示,达雷妥尤单抗联合方案及更早线治疗时结局更优。

要点

  • 全队列583例,中位随访17.5个月,中位PFS 13.1个月,中位OS 32.9个月。
  • 二线治疗中位PFS 23.5个月、OS 49.1个月;三线12.8和43.0个月;四线7.0和20.5个月。
  • 达雷妥尤单抗联合硼替佐米、来那度胺或泊马度胺较单药(联合或不联合糖皮质激素)中位PFS和OS更优。

核心结论

  • 这些来自CMRG-DB的回顾性数据提示,达雷妥尤单抗联合方案及更早线治疗时结局更优。

研究设计与样本

  • 回顾性队列研究,基于加拿大骨髓瘤研究组数据库(CMRG-DB),纳入583例接受达雷妥尤单抗为基础方案二线及以上治疗的复发难治性多发性骨髓瘤患者。

主要发现

  • 中位随访17.5个月,全队列中位PFS 13.1个月,中位OS 32.9个月。
  • 二线治疗中位PFS 23.5个月、中位OS 49.1个月;三线中位PFS 12.8个月、中位OS 43.0个月;四线中位PFS 7.0个月、中位OS 20.5个月。
  • 达雷妥尤单抗单药(联合或不联合糖皮质激素)在中位既往4线治疗后,中位PFS 3.9个月,中位OS 17.1个月。
  • 达雷妥尤单抗联合硼替佐米中位PFS 8.3个月、中位OS 26.2个月;联合来那度胺中位PFS 26.8个月、中位OS 43.0个月;联合泊马度胺中位PFS 9.7个月、中位OS 31.4个月。

临床怎么用

  • 原文结论提示达雷妥尤单抗联合方案及更早线治疗时结局更优,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Daratumumab (dara) has significantly altered the therapeutic landscape of multiple myeloma (MM), especially in the relapsed setting. This study aimed to evaluate the outcomes of dara-containing regimens in the Canadian real-world setting among relapsed and refractory MM available within the national Canadian Myeloma Research Group Database (CMRG-DB). A total of 583 MM patients who received dara-based therapy in second-line or later treatment were included. After a median follow-up of 17.5 months, the median progression-free survival (PFS) and overall survival (OS) for the entire cohort were 13.1 and 32.9 months, respectively. The median PFS and OS were 23.5 and 49.1 months in second-line treatment and decreased to 12.8 and 43.0 months in third-line and 7.0 and 20.5 months in fourth-line treatment respectively. Dara in monotherapy with or without corticosteroids after a median of four prior lines of therapy resulted in a median PFS of 3.9 months and a median OS of 17.1 months. The addition of bortezomib, lenalidomide or pomalidomide to dara resulted in an improved median PFS and OS of 8.3 and 26.2 months; 26.8 and 43.0 months; and 9.7 and 31.4 months respectively. These retrospective data from the CMRG-DB suggest that outcomes are superior when dara is used in combination and in earlier lines of treatment.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. LeBlanc R, Mian H, Reece D, et al. Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. Br J Haematol. 2022. PMID: 35383886. doi:10.1111/bjh.18172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。